Tetrathiomolybdate
- Generic Name
- Tetrathiomolybdate
- Drug Type
- Small Molecule
- Chemical Formula
- MoS4
- CAS Number
- 16330-92-0
- Unique Ingredient Identifier
- 91U3TGV99T
- Background
Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body.
- Indication
Investigated for use/treatment in liver disease and pulmonary fibrosis.
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
- Conditions
- Residual DiseaseTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 204
- Registration Number
- NCT06134375
- Locations
- πΊπΈ
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Early Access Program for ALXN1840 in Patients With Wilson Disease
- Conditions
- Wilson Disease
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT05686564
Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05641311
- Locations
- π¬π§
Richmond Pharmacology Ltd., St George's University of London, London, United Kingdom
A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05319899
- Locations
- πΊπΈ
Clinical Trial Site, Lincoln, Nebraska, United States
Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05303324
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05047523
- Locations
- πͺπΈ
Research Site, Pamplona, Spain
Bioavailability Study of 2 Oral Formulations of ALXN1840
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04610580
- Locations
- π¦πΊ
Nucleus Network Pty Ltd., Melbourne, Victoria, Australia
Copper Balance in Healthy Participants Administered ALXN1840
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04594252
- Locations
- π¬π§
Clinical Study Site, London, United Kingdom
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04573309
- Locations
- π¬π§
Research Site, London, United Kingdom
A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT04560816
- Locations
- πΊπΈ
PPD Development, LP, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.